• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

USPSTF recommends chemoprevention for women at high risk for breast cancer

bys25qthea
April 20, 2013
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Among high-risk women, the chemopreventative medications tamoxifen and raloxifene reduced the incidence of invasive breast cancer and fractures but increased the incidence of thromboembolic events. Neither medication impacted all-cause or breast cancer-specific mortality. 

2. While tamoxifen was more effective than raloxifene, it increased the incidence of thromboembolic events, endometrial cancer, and cataracts more than placebo or raloxifene. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: This systematic review of chemoprevention of breast cancer found that tamoxifen and raloxifene provide benefit to women at the highest level of risk for breast cancer and recommends prophylaxis for those women at high risk for breast cancer and low risk of adverse events. Adverse events on these medications include clots, endometrial cancer and cataracts such that clinicians should discuss the pros and cons of chemoprophylaxis with patients. The findings of this review serve as an update to the 2002 U.S. Preventive Services Task Force (USPSTF) evidence-based recommendations. Further investigations are required to facilitate more concrete treatment recommendations in future USPSTF reports. In particular, studies to characterize mortality benefit, define optimal treatment dose and duration, and identify practical methods of recognizing high-risk women are needed.

Click to read the study in The Annals of Internal Medicine

Relevant Reading: UptoDate: Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention

RELATED REPORTS

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

In-Depth [systematic review]: from the Agency for Healthcare Research and Quality (AHRQ) Effective Health Care Program included randomized, controlled trials, observational studies, and diagnostic accuracy studies of risk assessment. Studies from the last report in 2002 through December 5, 2012 were included. Two investigators independently reviewed each study, rated study quality and abstracted key data.

Composite data of four placebo-controlled trials in women without preexisting breast cancer found that tamoxifen prevented 7 cases of invasive breast cancer in 1000 women over 5 years (RR:0.70, CI:0.59-0.82). Two placebo-controlled trials found that raloxifene prevented 9 cases in 1000 women over 5 years (RR:0.44, CI:0.27-0.71). Head-to-head comparison of tamoxifen and raloxifene from the STAR (Study of Tamoxifen and Raloxifene) trial found that tamoxifen reduced breast cancer incidence more than raloxifene by 5 cases in 1000, but neither reduced mortality rates.  Both drugs were found to reduce the incidence of fractures by similar amounts, but tamoxifen increased the incidence of thromboembolic events, endometrial cancer, and cataracts more than placebo or raloxifene.

By Maren Shapiro and Leah Hawkins

More from this author:  Black men less likely to receive follow-up for elevated prostate cancer marker, PSA,  More U.S. women using emergency contraception pill, No-cost contraception reduces unintended pregnancies

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: Breast Cancerchemopreventionraloxifenetamoxifen
Previous Post

Contraband tobacco leads to reduced smoking cessation

Next Post

Light drinking during pregnancy may be safe

RelatedReports

Adjuvant radiation decreases local recurrence in low-risk breast cancer
Oncology

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

March 27, 2023
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

March 12, 2023
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Gastroenterology

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

March 8, 2023
#StudyGraphics: Adjuvant abemaciclib improves survival in patients  with hormone receptor-positive early breast cancer
StudyGraphics

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

March 8, 2023
Next Post
Light drinking during pregnancy may be safe

Light drinking during pregnancy may be safe

Classics Series, Landmark Trials in Medicine

The ALLHAT: Thiazide diuretics as first-line antihypertensive therapy [Classics Series]

Algorithm improves pediatric chronic cough outcomes

Algorithm improves pediatric chronic cough outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options